drugset / Trial / NCT01505907
Pharmacokinetic Study of CXB909 in Healthy Male Subjects
RandomizedSingle-groupTriple-blind
Summary
The primary objective of this dose escalation study is to examine the safety, tolerability, and pharmacokinetic properties of single-doses of CXB909, compared to placebo, in healthy male volunteers. This study may evaluate five (5) dose levels of CXB909; however, the number of dose levels, as well as the dosages, may be adjusted after evaluation of in-study analysis of the safety, tolerability, and pharmacokinetic data. This study will attempt to identify the maximum tolerated single dose of CXB909.
Timeline
- Start
- 2012-12
- Primary completion
- 2013-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CXB909 | Unknown | 15 mg | — |
| Subject | CXB909 | Unknown | 30 mg | — |
| Subject | CXB909 | Unknown | 60 mg | — |
| Subject | CXB909 | Unknown | 120 mg | — |
| Subject | CXB909 | Unknown | 250 mg | — |
Indications
No indication recorded.